Thus, BETi or HDACi may offer a synthetic lethality treatment strategy for pancreatic cancer upon KDM6A loss [48,49]; in this subset of cancer cells, a correlation between loss of KDM6A expression and poor prognosis was observed [49]. The gene discussed is KDM6A; the disease is pancreatic neoplasm.